Building and Implementing a Value-Proposition for Ready-to-Administer Products
ACPE Number:0204-0000-24-409-H04-P Content Release Date: February 13, 2025 Expiration Date: February 13, 2026 Activity Type: Application-based CE Credits: 1.5 contact hours (0.15 CEUs) 1.5 points (CPEL) Activity Fee: Free
Activity Overview
This educational activity will examine the evidence for the safety and cost-effectiveness of ready-to-administer (RTA) prefilled syringes compared to the traditional vial-and-syringe method. The data and information for building an institution-specific value proposition to persuade decision makers to adopt or expand use of RTA prefilled syringes will be discussed. Faculty will present implementation strategies for transitioning from vial and syringe to RTA prefilled syringes in different areas of the health system and in non-traditional sites.
*Please note, this activity was presented live on December 10, 2024 as part of the ASHP 2024 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity offers 1.5 live CPEL recertification points. Be sure to claim your CPEL certificate of participation when you process CE to track recertification credits earned.
This activity was planned to meet the educational needs of pharmacists in leadership positions including pharmacy executives, managers and supervisors, front-line clinical pharmacists and those in product procurement roles who can identify specific opportunities for realizing benefit from the use of Ready-to-Administer (RTA) prefilled syringes.
After participating in this CPE activity, learners should be able to:
Analyze peer-reviewed evidence supporting the cost-effectiveness of Ready-to-Administer (RTA) prefilled syringes compared to the traditional vial and syringe method.
Evaluate examples of a total value proposition for the adoption or expansion of RTA prefilled syringe use in their practice setting.
Identify a process for transitioning from traditional vial-and-syringe medications to RTA prefilled syringes.
John B. Hertig, PharmD, MS, CPPS, FASHP, FFIP is an Associate Professor and Past-Chair of the Pharmacy Practice Department in the Butler University College of Pharmacy and Health Sciences in Indianapolis, Indiana). Dr. Hertig lectures around the world and publishes on a variety of patient safety, leadership, administration, and health policy topics. He serves as an Associate Editor for the Journal of Medicine Access, and his extensive research program is designed to enhance the safety of the medication use process, while using evidence to inform patient advocacy efforts. Dr. Hertig is a Member of the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee. He holds other national and international appointments, including with the International Pharmaceutical Federation, where he is Treasurer for the Hospital Pharmacy Section, and as Past-President of the Board of Directors for the Alliance for Safe Online Pharmacies – Global (ASOP), where he leads efforts to reduce the patient safety impact of illegal and counterfeit online drug distribution worldwide. He was awarded the ASOP Global Patient Safety Champion Award in 2018. Dr. Hertig received his Bachelor of Science in Pharmaceutical Sciences and Doctor of Pharmacy degrees from Purdue University. He completed a PGY1 pharmacy practice and PGY2 health-system pharmacy administration residency at The Ohio State University Medical Center while also obtaining a Masters degree in Health-System Pharmacy Administration from The Ohio State University.
Noelle RM Chapman, PharmD, MBA, BCPS, FASHP VP, Chief Pharmacy Officer UCSF Health Associate Dean UCSF School of Pharmacy San Francisco, California
Noelle RM Chapman, PharmD, MBA, BCPS, FASHP is Chief Pharmacy Officer and Associate Dean at the University of California, San Francisco Health in San Francisco, California. Noelle received her Doctor of Pharmacy degree from the University of Wisconsin and completed her MBA at New England College. She completed a residency at Northwestern Memorial Hospital, is a graduate of the Pharmacy Leadership Academy, and was named as a fellow of ASHP in 2015. Dr. Chapman is an active member of the American Pharmacists Association, Vizient Pharmacy Network, and the California Society of Health System Pharmacy in addition to ASHP.
Ryan Haumschild, PharmD, MS, MBA , CPEL Vice President of Ambulatory Pharmacy Emory Healthcare Winship Cancer Institute Atlanta, Georgia
Ryan Haumschild, PharmD, MS, MBA is an experienced Vice President of Ambulatory Pharmacy at Emory Healthcare and Winship Cancer Institute overseeing profit & loss responsibility, pharmacy operations, clinical services, formulary management, payer and health plan contracting, and medication use across one of the nation’s largest academic integrated delivery networks and Georgia’s only NCI-Designated Comprehensive Cancer Center. Ryan provides strategic direction within oncology and non-oncology disease states, infusion and specialty pharmacy services, and the expansion of clinical services through treatment pathway development. He has achieved the Certified Pharmacy Executive Leader (CPEL) designation from ASHP which represents the highest credential for an executive pharmacy leader by acknowledging unique expertise and provides national recognition of core competencies in professionalism, leading people, leading the pharmacy enterprise, and leading within and across complex integrated delivery networks. Ryan currently serves as an Editorial Board Member at the American Journal of Managed Care® (AJMC®), Board member for both the Institute of Safe Medication Practices (ISMP) and Center for Biosimilars, and was recently recognized as 40 under 40 by three separate organizations: University of Florida, Atlanta Business Chronicle, and Association for Value-Based Cancer Care
Jeffery S. Vender, MD, MCCM, MBA is the Emeritus, Harris Family Foundation Chairman of the Department of Anesthesiology at NorthShore University Health System in Evanston, Illinois and a Clinical Professor at the University of Chicago Pritzker School Of Medicine in Chicago, Illinois. He is a past member of the NorthShore University Health System Faculty Practice Associates Board of Directors, Past Chair of the Medical Executive Committee for the Professional Staff at NorthShore and previously served on Northshore’s Board of Directors. Dr. Vender served as Chair of Anesthesia from 1990-2015 and received an appointment of adjunct Professor of Biomedical Engineering at Northwestern University. He served as the Director of the Critical Care Services at Evanston Hospital from 1987-2000 and the Interim Chairman at Northwestern University Department of Anesthesiology from July 1999 until October 2000. Dr. Vender has participated and Chaired numerous state and national committees of various medical organizations, edited several medical texts, has published over 135 articles and book chapters and has been an invited lecturer at over 250 national and international meetings on topics of anesthesiology, critical care, organizational change, and leadership. In addition, Dr. Vender serves as an editor and/or reviewer for many medical journals.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
John Hertig – Fresenius Kabi, USA: Investigator
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.
Provided by ASHP
Supported by an educational grant from Fresenius-Kabi USA, LLC.